Deerfield Management Company, L.P. (Series C) Silverback Therapeutics, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SBTX
# of Institutions
131Shares Held
62MCall Options Held
1.37MPut Options Held
83.8K-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA9.24MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.25MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...